Niagen Bioscience Reveals Findings from Groundbreaking Randomized Controlled Trial on Niagen (Patented Nicotinamide Riboside, NR) Supplementation for Long COVID
Clinical Trial Findings: A clinical trial published in The Lancet showed that daily supplementation with Niagen® significantly increased NAD+ levels and improved symptoms such as fatigue, depression, and sleep quality in individuals with long COVID.
Study Overview: The randomized, double-blind, placebo-controlled study involved 58 participants and demonstrated within-group improvements in cognitive performance and other symptoms, although no statistically significant differences were found between the Niagen and placebo groups.
Importance of NAD+: The study highlights the potential role of NAD+ restoration in addressing long COVID symptoms, suggesting that it may help restore biological pathways affected by the condition, including mitochondrial function and cellular repair.
Future Research Directions: While the findings are promising, further large-scale studies are needed to confirm the results and better understand the therapeutic potential of NAD+ in post-viral recovery and energy metabolism.
Trade with 70% Backtested Accuracy
Analyst Views on NAGE
About NAGE
About the author
Doseology Sciences Acquires Feed That Brain for $400,000, Expanding into Performance Wellness Market
- Strategic Acquisition: Doseology Sciences acquired the Feed That Brain brand for $400,000, marking a strategic expansion into the performance wellness segment, which is expected to accelerate the Canadian launch of next-generation clean energy pouches.
- Executive Appointment: Concurrently, the company appointed Joseph Mimran as Strategic Advisor under a three-year agreement valued at $400,000 in restricted share units, aiming to leverage his extensive experience in retail and brand building to drive business growth.
- Market Potential: According to Grand View Research, the global energy drinks market is projected to grow from $79.4 billion in 2024 to $125.1 billion by 2030, while the nicotine pouch category is expected to expand from $5.4 billion to over $25 billion at a 29.6% CAGR, indicating strong growth potential for Doseology's market positioning.
- Product Innovation: Doseology's U.S. subsidiary is developing pouch-based offerings that blend caffeine, nootropics, and adaptogens, designed to provide sugar-free, smoke-free alternatives for professionals and wellness consumers seeking functional stimulation, further solidifying its competitive edge in the health tech sector.
Niagen Bioscience Introduces Tru Niagen® Beauty — The First NAD+ Skincare Supplement in the U.S. with Patented Niagen® (Nicotinamide Riboside)
Launch of Tru Niagen® Beauty: Niagen Bioscience has introduced Tru Niagen® Beauty, the first beauty supplement in the U.S. featuring Niagen (nicotinamide riboside), aimed at enhancing skin, hair, and nail health through cellular support.
Key Ingredients and Benefits: The supplement contains a blend of clinically studied ingredients, including Astaxanthin, Hyaluronic Acid, Grape Seed Extract, Biotin, and Vitamin E, designed to improve skin hydration, elasticity, and overall beauty from within.
Market Growth Potential: The U.S. astaxanthin market is projected to grow significantly, reflecting increasing consumer demand for natural antioxidants and health supplements, while the global nutricosmetics market is also expected to expand rapidly.
Commitment to Scientific Research: Niagen Bioscience emphasizes its dedication to advancing healthspan through evidence-based innovations and rigorous scientific research, positioning itself as a leader in NAD+ science and healthy aging.
